ABEONA THERAPEUTICS INC
ABEONASDAQTrading Snapshot
- Day Range
- $5.21 – $5.33
- 52-Week Range
- $4.00 – $7.65
- Volume
- $2.70B
- Avg Volume
- $2.20B
- Shares Outstanding
- 57.0M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $11M
- P/E Ratio
- -4.7
- P/S Ratio
- 11.8x
- EPS (TTM)
- $-1.10
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +61.1%
Why Investors Own ABEO
- ✓High-growth profile — revenue up -8.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ABEONA THERAPEUTICS INC
ABEO
StockOtter · stockotter.spaceAbout ABEONA THERAPEUTICS INC
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Dan
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
Abeona Therapeutics NASDAQ: ABEO highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwrigh
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
Abeona Therapeutics NASDAQ: ABEO executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Abeona Therapeutics Inc. (NASDAQ:ABEO) had a busy week that included a new treatment center activation, an FDA approval for a drug the company licensed away and multiple fresh analyst ratings.
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts -
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript